Stock AnalizBiohaven Ltd. BHVN
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
Biohaven Ltd. (BHVN) is a healthcare company listed in the US with a market value of about $2.1B.
Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -191%.
Score: 0.0 / 5
Checks passed
- —
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$739M | -$846M | -$408M | -$570M | -$214M | -$119M |
| Free cash flow | -$610M | -$587M | -$335M | -$304M | -$147M | -$77M |
| EPS (diluted) | $-6.86 | $-9.28 | $-5.73 | $-12.75 | $-5.43 | $-3.01 |
| Net margin | — | — | — | — | — | — |
| ROIC | -174.9% | -152.0% | -94.7% | -78.4% | -456.0% | -682.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $23.73, 72% above the current price; targets range from $9.00 to $48.00; the consensus rating is “Buy”; expected EPS is $-1.39 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Biohaven pay a dividend?
Not currently.
Is Biohaven a good stock to buy?
We do not give buy or sell advice. Biohaven scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.